SCHEMBL9246804

SCHEMBL9246804

O=c1c2ccc(Cl)cc2oc2ccc(O)cc12

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 4/20 0.66
TTR P02766 3/20 0.62
ESR2 Q92731 2/20 0.58
ESR1 P03372 1/20 0.54
MGAM O43451 1/20 0.53
FASN P49327 1/20 0.53
AHR P35869 1/20 0.50
KDM4E B2RXH2 2/20 0.49
MAPT P10636 2/20 0.49
HSD17B10 Q99714 2/20 0.49
CA12 O43570 1/20 0.49
CA9 Q16790 1/20 0.49
MEN1 O00255 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C9 P11712 1/20 0.49
KMT2A Q03164 1/20 0.49
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.48
ALOX15 P16050 1/20 0.48
HTT P42858 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9252118 0.92 MAOA (0.67) MAOATTRESR2ESR1AHR
SCHEMBL31423805 0.88 MAOA (0.77) MAOAESR2ESR1MGAMFASN
SCHEMBL7337235 0.88 MAOA (0.77) MAOAESR2ESR1MGAMFASN
SCHEMBL9250307 0.88 TTR (0.57) MAOATTRESR2AHRKDM4E
SCHEMBL2768245 0.86 AHR (0.61) MAOATTRESR2ESR1AHR
SCHEMBL11728871 0.84 TTR (0.71) MAOATTRAHRKDM4EMAPT
Euxanthone SCHEMBL2161295 0.84 MAOA (0.81) MAOAESR2ESR1MGAMFASN
SCHEMBL29465920 0.84 TTR (0.71) MAOATTRAHRKDM4EMAPT
SCHEMBL10913158 0.81 KDM4E (0.75) MAOATTRAHRKDM4EMAPT
SCHEMBL24343643 0.81 AHR (0.62) MAOATTRESR2ESR1MGAM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2842937-B1 AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES MITSUBISHI TANABE PHARMA CORP (JP) 2018-01-17 EP disclosed
US-9657043-B2 Amine compound and use thereof for medical purposes MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-05-23 US disclosed
US-9657043-B2 Amine compound and use thereof for medical purposes MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-05-23 US disclosed
US-9657043-B2 Amine compound and use thereof for medical purposes MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-05-23 US disclosed
US-20150087620-A1 AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-03-26 US disclosed
US-20150087620-A1 AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-03-26 US disclosed
US-20150087620-A1 AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-03-26 US disclosed
EP-2842937-A1 AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES Mitsubishi Tanabe Pharma Corporation (JP) 2015-03-04 EP disclosed
US-5395914-A Nucleophilic polycondensation of hydroxy halogen xanthones HOECHST AKTIENGESELLSCHAFT (DE) 1995-03-07 US disclosed
EP-0571883-A1 Polyarylethers with xanthone units, method for their production and their application HOECHST AKTIENGESELLSCHAFT (DE) 1993-12-01 EP disclosed
US-4954604-A High molecular weight, crystalline BAYER AKTIENGESELLSCHAFT (DE) 1990-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150087620-A1 AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES HLA-B, HLA-A, HLA-C MAOA 131/4885TTR 2178/4885ESR2 2804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.